“Big Data”, “Precision Medicine” and “Machine Learning” are praised as the solution of all problems in psychiatry. However, critical questions are rarely discussed.
The Institute for Quality and Efficiency in Health Care (IQWiG) on July 16, 2018, published its opinion on cariprazine as part of its „benefit assessment“. It concludes that there is an “indication” that cariprazine has a “non-quantifiable added benefit” in the group of patients with schizophrenia with predominant negative symptoms.
The problem of withdrawal syndromes and emotional blunting occurring with prolonged antidepressant treatment is constantly underestimated by clinicians.